Roschlotin Use In Pregnancy & Lactation

Pregnancy Category X. Rosuvastatin is contraindicated for use in pregnant women since safety in pregnant women has not been established and there is no apparent benefit of lipid-lowering drugs during pregnancy. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, Rosuvastatin may cause fetal harm when administered to a pregnant woman. The use of Rosuvastatin should be discontinued as soon as pregnancy is recognized.
Rosuvastatin use is contraindicated during breastfeeding. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. It is not known whether Rosuvastatin is present in human milk, but it has been shown that another drug in this class passes into human milk and Rosuvastatin is present in rat milk. Because of the potential for serious adverse reactions in a breastfed infant, women should be advised that breastfeeding is not recommended during treatment with Rosuvastatin.